Over the last four quarters, the company has surpassed consensus EPS estimates two times. Kiniksa Pharmaceuticals International, plc, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $156.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.92$108.63 million. The company has topped consensus revenue estimates four times over the last four quarters. Kiniksa Pharmaceuticals International, plc ( ...